gp100 Peptide Vaccine and Interleukin-2 in Patients with Advanced Melanoma

J. Schwartzentruber, Douglas; H. Lawson, David; Richards, Jon; M. Conry, Robert; M. Miller, Donald; Treisman, Jonathan; Gailani, Fawaz; B. Riley, Lee; C. Conlon, Kevin; A. Pockaj, Barbara; Kendra, Kari; L. White, Richard; González, René; M. Kuzel, Timothy; D. Curti, Brendan; D. Leming, Phillip; D. Whitman, Eric; Balkissoon, Jai; S. Reintgen, Douglas; L. Kaufman, Howard; M. Marincola, Francesco; J. Merino, Maria; A. Rosenberg, Steven; L. Choyke, Peter; Vena, Don; Hwu, Patrick

doi:10.1056/nejmoa1012863

Public

gp100 Peptide Vaccine and Interleukin-2 in Patients with Advanced Melanoma

Published in New England Journal of Medicine • Jun 1, 2011

Authors:

Douglas J. Schwartzentruber

David H. Lawson

Jon Richards

Abstract

BACKGROUND: Stimulating an immune response against cancer with the use of vaccines remains a challenge. We hypothesized that combining a melanoma vaccine with interleukin-2, an immune activating agent, could improve outcomes. In a previous phase 2 study, patients with metastatic melanoma receiving h...

Subject

Medicine

Clinical endpoint

Internal medicine

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!